Integrating the multiple breath washout test into international multicentre trials
Forced expiratory volume in 1 s (FEV1), measured by spirometry, has been a primary endpoint in cystic fibrosis (CF) clinical trials for many decades. However, as lung function improves for patients with CF, FEV1 now remains in the normal range for the majority of paediatric patients and a significant proportion of adults [1,2] . The insensitivity of FEV1 to detect early lung disease and the beneficial effect of interventions has been highlighted by studies comparing spirometry with more sensitive lung function tests and imaging-based assessments of structural disease [2–5].
Source: Journal of Cystic Fibrosis - Category: Respiratory Medicine Authors: Clare Saunders, Renee Jensen, Paul D. Robinson, Sanja Stanojevic, Michelle Klingel, Christopher Short, Jane C. Davies, Felix Ratjen Tags: Original Article Source Type: research
More News: Clinical Trials | Cystic Fibrosis | Pediatrics | Respiratory Medicine | Spirometry | Study